Kuzuoglu-Ozturk et al. showcase a therapeutic approach, “translatome therapy,” to combat lethal prostate cancer. Zotatifin, a clinical molecule, targets the RNA-helicase eIF4A. Zotatifin decreases the select translation of key oncogenes, androgen receptor (AR), and HIF1α through remodeling their 5′ UTR RNA structure. Zotatifin enhances anti-androgen and radiotherapy sensitivity, highlighting a promising anti-cancer treatment.

Transcriptome-wide mapping of snoRNA targets reveals mRNA-snoRNA-7SL RNA ternary interactions, which facilitate nascent protein translocation to the ER and subsequent secretion.

Zhou et al. discovered a specific role of adenosine modifications in the coding region of mRNAs. These chemical alterations slow down the movement of the ribosome during translation and trigger degrad...

The CCR4-NOT complex is a major regulator of eukaryotic messenger RNA (mRNA) stability. Slow decoding during translation promotes association of CCR4-NOT with ribosomes, accelerating mRNA degradation....